1. Cell Cycle/DNA Damage Cytoskeleton Protein Tyrosine Kinase/RTK Autophagy Apoptosis
  2. Microtubule/Tubulin Bcr-Abl CRISPR/Cas9 Autophagy Apoptosis
  3. Nocodazole

Nocodazole  (Synonyms: Oncodazole; R17934)

Cat. No.: HY-13520 Purity: 99.59%
SDS COA Handling Instructions

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl, and activates CRISPR/Cas9.

For research use only. We do not sell to patients.

Nocodazole Chemical Structure

Nocodazole Chemical Structure

CAS No. : 31430-18-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 70 publication(s) in Google Scholar

Top Publications Citing Use of Products

67 Publications Citing Use of MCE Nocodazole

WB
IF

    Nocodazole purchased from MedChemExpress. Usage Cited in: Science. 2022 Nov 18;378(6621):eabq7361.  [Abstract]

    Representative time-lapse images (z-stack) showing microtubule nucleation after nocodazole washout in live human oocytes. Gray, microtubules (GFP-MAP4); magenta, kinetochores (mScarlet-CENPB).
    Flow diagram shows the sequence of experiments. Arrow indicates timelapse imaging initiation. Time is given as hours: minutes after nocodazole washout.

    Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.  [Abstract]

    Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).

    Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.  [Abstract]

    Immunofluorescence imaging of LNCaP cells treated with the Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ( (-) Bl). After the cells are cultured on different substrates for 3 days, inhibitors are added and incubated for 24 h.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl, and activates CRISPR/Cas9.

    IC50 & Target[1]

    Abl

    91 nM (Kd)

    ABL(E255K)

    120 nM (Kd)

    ABL(T315I)

    170 nM (Kd)

    BRAF

    1.8 μM (Kd)

    BRAF(V600E)

    1.1 μM (Kd)

    c-KIT

    1.6 μM (Kd)

    MEK1

    1.7 μM (Kd)

    MEK2

    1.6 μM (Kd)

    MET

    1.7 μM (Kd)

    PI3Kγ

    1.5 μM (Kd)

    Microtubule/Tubulin

     

    CRISPR/Cas9

     

    Cellular Effect
    Cell Line Type Value Description References
    4T1 IC50
    1.3 μM
    Compound: Nocodazole
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    A-375 IC50
    0.2 μM
    Compound: Nocodazole
    Anticancer activity against human A375 cells by MTT assay
    Anticancer activity against human A375 cells by MTT assay
    10.1039/C4MD00219A
    A549 GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells after 48 hrs by SRB cell proliferation assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB cell proliferation assay
    [PMID: 29089233]
    A549 IC50
    < 0.1 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
    10.1039/C0MD00263A
    A549 GI50
    < 0.1 μM
    Compound: Nocodozole
    Growth inhibition of human A549 cells by Sulforhodamine B assay
    Growth inhibition of human A549 cells by Sulforhodamine B assay
    [PMID: 21106458]
    A549 GI50
    0.02 μM
    Compound: Nocadazole
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 25827522]
    A549 GI50
    0.08 μM
    Compound: Nocodazole
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 27130357]
    A549 IC50
    0.087 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21954851]
    A549 GI50
    0.09 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 28117204]
    A549 IC50
    0.12 μM
    Compound: 1
    Growth inhibition of human A549 cells after 72 hrs by MTT assay
    Growth inhibition of human A549 cells after 72 hrs by MTT assay
    [PMID: 25262051]
    A549 IC50
    0.13 μM
    Compound: 4
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    10.1039/C5MD00150A
    A549 IC50
    0.2 μM
    Compound: Ncz
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    A549 GI50
    0.21 μM
    Compound: Nocodazole
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00177E
    A549 IC50
    0.272 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter96 Aqueous one solution cell proliferation assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter96 Aqueous one solution cell proliferation assay
    [PMID: 32551013]
    A549 GI50
    0.5 μM
    Compound: Nocodozole
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 20529689]
    A549 IC50
    0.82 μM
    Compound: 2
    Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 30108808]
    A549 IC50
    0.89 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25599948]
    A549 IC50
    0.9 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 28988624]
    A549 IC50
    1.05 μM
    Compound: 3
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30108921]
    A549 IC50
    1.38 μM
    Compound: Nacodazole
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    A549 IC50
    1.393 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30108815]
    A549 IC50
    1.513 μM
    Compound: Nocodazole
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 28789894]
    A549 IC50
    1.62 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    10.1039/C4MD00400K
    A549 IC50
    1.807 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    [PMID: 33316752]
    A549 IC50
    1.807 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay
    [PMID: 31926469]
    A549 IC50
    1.87 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 28668476]
    A549 IC50
    1.87 μM
    Compound: Nocodazole
    Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    [PMID: 26231080]
    A549 EC50
    106.5 nM
    Compound: Nocodazole
    Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by flow cytometry
    Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by flow cytometry
    [PMID: 20110137]
    A549 IC50
    2.3 μM
    Compound: Nocodazole
    Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 28684120]
    A549 IC50
    2.31 μM
    Compound: nocodazole
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 23748152]
    A549 IC50
    2.5 μM
    Compound: Nocodazole
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    10.1039/C4MD00219A
    A549 IC50
    3.63 μM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717368]
    A549 IC50
    36.6 nM
    Compound: Nocodazole
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 20110137]
    B16 IC50
    0.69 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    10.1039/C4MD00400K
    B16-F10 IC50
    3.12 μM
    Compound: Nocodazole
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717368]
    BT-474 IC50
    0.87 μM
    Compound: Nocodazole
    Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 34095841]
    BT-474 IC50
    2.72 μM
    Compound: Nocodazole
    Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717368]
    BT-549 IC50
    0.069 μM
    Compound: Nocodazole
    Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    CAPAN-1 IC50
    0.13 μM
    Compound: Nocodazole
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    COLO 205 IC50
    0.088 μM
    Compound: Nocodazole
    Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    Cortical neurone IC50
    0.097 μM
    Compound: Nocodazole
    Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    [PMID: 31841637]
    Cortical neurone IC50
    0.0997 μM
    Compound: Nocodazole
    Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    [PMID: 31841637]
    Cortical neurone IC50
    2.22 μM
    Compound: Nocodazole
    Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
    [PMID: 31841637]
    DLD-1 IC50
    0.19 μM
    Compound: Nocodazole
    Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    DU-145 IC50
    < 0.1 μM
    Compound: Nocodazole
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay
    10.1039/C0MD00263A
    DU-145 GI50
    0.011 μM
    Compound: Nacodazole
    Antiproliferative activity against human DU145 cells by SRB assay
    Antiproliferative activity against human DU145 cells by SRB assay
    [PMID: 31546197]
    DU-145 GI50
    0.19 μM
    Compound: Nocodazole
    Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00177E
    DU-145 IC50
    0.25 μM
    Compound: Nocodazole
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    10.1039/C4MD00400K
    DU-145 IC50
    1.14 μM
    Compound: Nocodazole
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    DU-145 IC50
    1.259 μM
    Compound: Nocodazole
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 30108815]
    DU-145 IC50
    1.38 μM
    Compound: Nacodazole
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    DU-145 IC50
    1.39 μM
    Compound: 3
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 30108921]
    DU-145 IC50
    1.698 μM
    Compound: Nocodazole
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 28789894]
    DU-145 IC50
    2.1 μM
    Compound: Nocodazole
    Anticancer activity against human DU145 cells by MTT assay
    Anticancer activity against human DU145 cells by MTT assay
    10.1039/C4MD00219A
    DU-145 IC50
    2.2 μM
    Compound: Nocodazole
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    DU-145 IC50
    2.8 μM
    Compound: nocodazole
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 23748152]
    DU-145 IC50
    3.2 μM
    Compound: Nocodazole
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25599948]
    HaCaT IC50
    1.19 μM
    Compound: Nocodazole
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 34095841]
    HaCaT IC50
    8.9 μM
    Compound: Nocodazole
    Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    [PMID: 26231080]
    HCT-116 IC50
    0.13 μM
    Compound: Nocodazole
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    HCT-116 IC50
    0.173 μM
    Compound: Nocodazole
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    [PMID: 21954851]
    HCT-116 IC50
    1.06 μM
    Compound: Nocodazole
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    HCT-116 IC50
    1.262 μM
    Compound: Nocodazole
    Anticancer activity against human HCT116 cells after 48 hrs by MTT assay
    Anticancer activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 28789894]
    HCT-116 IC50
    1.38 μM
    Compound: Nacodazole
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HCT-116 IC50
    2.82 μM
    Compound: Nocodazole
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717368]
    HEK293 IC50
    2.2 μM
    Compound: Nacodazole
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HEK293 IC50
    5.1 μM
    Compound: Nocodazole
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    HeLa GI50
    < 0.01 μM
    Compound: Nacodazole
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31546197]
    HeLa GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB cell proliferation assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB cell proliferation assay
    [PMID: 29089233]
    HeLa GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 27688193]
    HeLa GI50
    0.011 μM
    Compound: Nacodazole
    Antiproliferative activity against human HeLa cells by SRB assay
    Antiproliferative activity against human HeLa cells by SRB assay
    [PMID: 31546197]
    HeLa GI50
    0.015 μM
    Compound: Nocadazole
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 25827522]
    HeLa GI50
    0.063 μM
    Compound: Nocodazole
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 27130357]
    HeLa GI50
    0.086 μM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 28117204]
    HeLa IC50
    0.3 μM
    Compound: Ncz
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    HeLa IC50
    0.71 μM
    Compound: nocodazole
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 23748152]
    HeLa GI50
    0.75 μM
    Compound: Nocodazole
    Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00177E
    HeLa GI50
    0.75 μM
    Compound: Nocodozole
    Growth inhibition of human HeLa cells by Sulforhodamine B assay
    Growth inhibition of human HeLa cells by Sulforhodamine B assay
    [PMID: 21106458]
    HeLa GI50
    0.81 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 27344493]
    HeLa GI50
    0.81 μM
    Compound: 6
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 25131956]
    HeLa IC50
    0.84 μM
    Compound: 2
    Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
    [PMID: 30108808]
    HeLa IC50
    1.05 μM
    Compound: 3
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30108921]
    HeLa IC50
    1.1 μM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25599948]
    HeLa IC50
    1.11 μM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 34095841]
    HeLa IC50
    1.2 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 28988624]
    HeLa IC50
    1.6 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
    [PMID: 28684120]
    HeLa IC50
    1.611 μM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30108815]
    HeLa IC50
    178 nM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells after 24 to 48 hrs by trypan blue assay
    Cytotoxicity against human HeLa cells after 24 to 48 hrs by trypan blue assay
    [PMID: 23445405]
    HeLa IC50
    2.23 μM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    10.1039/C4MD00400K
    HeLa IC50
    2.83 μM
    Compound: Nocodazole
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 28668476]
    HeLa IC50
    2.83 μM
    Compound: Nocodazole
    Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    [PMID: 26231080]
    HeLa EC50
    40 nM
    Compound: Nocodazole
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth after 48 hrs by resazurin dye based fluorescence assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth after 48 hrs by resazurin dye based fluorescence assay
    [PMID: 31735573]
    HepG2 GI50
    < 0.01 μM
    Compound: Nacodazole
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31546197]
    HepG2 IC50
    < 0.1 μM
    Compound: Nocodazole
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by SRB assay
    10.1039/C0MD00263A
    HepG2 GI50
    0.011 μM
    Compound: Nacodazole
    Antiproliferative activity against human HepG2 cells by SRB assay
    Antiproliferative activity against human HepG2 cells by SRB assay
    [PMID: 31546197]
    HepG2 IC50
    0.4 μM
    Compound: Ncz
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    HepG2 GI50
    0.76 μM
    Compound: Nocodazole
    Growth inhibition of human HepG2 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HepG2 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00177E
    HepG2 IC50
    1.1 μM
    Compound: Nocodazole
    Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    [PMID: 28684120]
    HL-60 IC50
    0.1 μM
    Compound: Nocodazole
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    HMEC IC50
    11.5 μM
    Compound: Ncz
    Antiproliferative activity against human HMEC cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HMEC cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    HT-1080 IC50
    0.14 μM
    Compound: 1
    Growth inhibition of human HT1080 cells after 72 hrs by MTT assay
    Growth inhibition of human HT1080 cells after 72 hrs by MTT assay
    [PMID: 25262051]
    HT-1080 IC50
    0.15 μM
    Compound: 4
    Antiproliferative activity against human HT1080 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    10.1039/C5MD00150A
    HT-29 IC50
    2.2 μM
    Compound: Nacodazole
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    IMR-32 GI50
    < 0.01 μM
    Compound: Nacodazole
    Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31546197]
    IMR-32 IC50
    1.3 μM
    Compound: Nocodazole
    Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
    Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
    [PMID: 28988624]
    K562 IC50
    0.07 μM
    Compound: Nocodazole
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    K562 IC50
    0.22 μM
    Compound: Nocodazole
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 33212157]
    KB IC50
    0.14 μM
    Compound: Nocodazole
    Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
    Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
    [PMID: 21705223]
    KB IC50
    0.14 μM
    Compound: Nocodazole
    Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
    Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
    [PMID: 20537765]
    KB IC50
    0.14 μM
    Compound: nocodazole
    Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
    Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
    [PMID: 17973361]
    KB IC50
    0.14 μM
    Compound: nocodazole
    Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
    Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
    [PMID: 17181164]
    KB IC50
    0.14 μM
    Compound: nocodazole
    Antiproliferative activity against human KB/HeLa cells by XTT assay
    Antiproliferative activity against human KB/HeLa cells by XTT assay
    [PMID: 19220018]
    KB IC50
    0.14 μM
    Compound: Nocodazole
    Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    [PMID: 12852768]
    KB EC50
    91 nM
    Compound: Nocodazole
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
    [PMID: 20537765]
    KB EC50
    91 nM
    Compound: nocodazole
    Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
    Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
    [PMID: 19220018]
    KB EC50
    91 nM
    Compound: Nocodazole
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
    [PMID: 21705223]
    KB EC50
    91 nM
    Compound: nocodazole
    Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
    Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
    [PMID: 17973361]
    KB EC50
    91 nM
    Compound: nocodazole
    Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
    Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
    [PMID: 17181164]
    L02 IC50
    13.5 μM
    Compound: Ncz
    Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    L1210 IC50
    > 5 μM
    Compound: nocodazole
    Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
    Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
    [PMID: 19220018]
    L1210 IC50
    0.05 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    L1210 IC50
    0.05 μM
    Compound: nocodazole
    Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
    Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    L1210 IC50
    0.06 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    L1210 IC50
    0.06 μM
    Compound: nocodazole
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    [PMID: 19220018]
    L1210 IC50
    0.06 μM
    Compound: nocodazole
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    L1210 IC50
    0.07 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    L1210 IC50
    0.07 μM
    Compound: nocodazole
    Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    L1210 IC50
    0.09 μM
    Compound: Nocodazole
    Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
    Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    L1210 IC50
    0.09 μM
    Compound: nocodazole
    Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
    Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
    [PMID: 17181164]
    LN-229 IC50
    0.1 μM
    Compound: Nocodazole
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    LT12 tumor cell line IC50
    0.006 μM
    Compound: nocodazole
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    [PMID: 19220018]
    LT12 tumor cell line IC50
    0.04 μM
    Compound: Nocodazole
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    LT12 tumor cell line IC50
    0.04 μM
    Compound: Nocodazole
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    LT12 tumor cell line IC50
    0.04 μM
    Compound: nocodazole
    Antiproliferative activity against LT12 cells by XTT assay after 48 hrs
    Antiproliferative activity against LT12 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    LT12 tumor cell line IC50
    0.07 μM
    Compound: Nocodazole
    Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay
    Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    LT12 tumor cell line IC50
    0.07 μM
    Compound: Nocodazole
    Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay
    Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    LT12 tumor cell line IC50
    0.4 μM
    Compound: nocodazole
    Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay
    Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay
    [PMID: 19220018]
    MCF7 GI50
    < 0.01 μM
    Compound: Nacodazole
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31546197]
    MCF7 GI50
    < 0.1 μM
    Compound: Nocodozole
    Growth inhibition of human MCF7 cells by Sulforhodamine B assay
    Growth inhibition of human MCF7 cells by Sulforhodamine B assay
    [PMID: 21106458]
    MCF7 IC50
    0.2 μM
    Compound: Ncz
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    MCF7 IC50
    0.42 μM
    Compound: Nocodazole
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    MCF7 GI50
    0.94 μM
    Compound: Nocodazole
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    [PMID: 27344493]
    MCF7 GI50
    0.94 μM
    Compound: 6
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 25131956]
    MCF7 IC50
    1.086 μM
    Compound: Nocodazole
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 30108815]
    MCF7 IC50
    1.25 μM
    Compound: Nocodazole
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    [PMID: 28988624]
    MCF7 IC50
    1.48 μM
    Compound: 3
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 30108921]
    MCF7 IC50
    1.5 μM
    Compound: Nocodazole
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    [PMID: 28684120]
    MCF7 IC50
    1.6 μM
    Compound: Nocodazole
    Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    [PMID: 26231080]
    MCF7 IC50
    1.7 μM
    Compound: Nocodazole
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25599948]
    MCF7 IC50
    1.76 μM
    Compound: Nocodazole
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 34095841]
    MDA-MB-231 GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB cell proliferation assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB cell proliferation assay
    [PMID: 29089233]
    MDA-MB-231 GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    [PMID: 27688193]
    MDA-MB-231 IC50
    < 0.1 μM
    Compound: Nocodazole
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    10.1039/C0MD00263A
    MDA-MB-231 GI50
    0.011 μM
    Compound: Nacodazole
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    [PMID: 31546197]
    MDA-MB-231 GI50
    0.017 μM
    Compound: Nocadazole
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    [PMID: 25827522]
    MDA-MB-231 GI50
    0.042 μM
    Compound: Nocodazole
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    [PMID: 27130357]
    MDA-MB-231 GI50
    0.065 μM
    Compound: Nocodazole
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 28117204]
    MDA-MB-231 GI50
    0.15 μM
    Compound: Nocodazole
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00177E
    MDA-MB-231 IC50
    0.71 μM
    Compound: 2
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    [PMID: 30108808]
    MDA-MB-231 IC50
    1.1 μM
    Compound: Nocodazole
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    MDA-MB-231 IC50
    1.38 μM
    Compound: Nacodazole
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    MDA-MB-231 IC50
    1.83 μM
    Compound: Nocodazole
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717368]
    MDA-MB-231 IC50
    1.862 μM
    Compound: Nocodazole
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 28789894]
    MDA-MB-231 IC50
    1.9 μM
    Compound: Nocodazole
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    [PMID: 33316752]
    MDA-MB-453 IC50
    0.91 μM
    Compound: Nocodazole
    Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    MDR IC50
    0.07 μM
    Compound: nocodazole
    Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
    Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
    [PMID: 17181164]
    ME-180 IC50
    1.7 μM
    Compound: Nocodazole
    Anticancer activity against human ME180 cells by MTT assay
    Anticancer activity against human ME180 cells by MTT assay
    10.1039/C4MD00219A
    MIA PaCa-2 IC50
    0.91 μM
    Compound: 2
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by sulforhodamine B assay
    [PMID: 30108808]
    MIA PaCa-2 GI50
    0.95 μM
    Compound: Nocodazole
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by SRB assay
    [PMID: 27344493]
    MIA PaCa-2 GI50
    0.95 μM
    Compound: 6
    Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 25131956]
    MRC5 IC50
    15.3 μM
    Compound: Ncz
    Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30878833]
    NCI-H460 IC50
    0.068 μM
    Compound: Nocodazole
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    NCI-H460 IC50
    0.15 μM
    Compound: Nocodazole
    Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    NCI-H460 IC50
    0.15 μM
    Compound: Nocodazole
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    NCI-H460 IC50
    0.15 μM
    Compound: nocodazole
    Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    NCI-H460 IC50
    0.15 μM
    Compound: nocodazole
    Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
    Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    NCI-H460 IC50
    0.15 μM
    Compound: nocodazole
    Antiproliferative activity against human NCI-H460 cells by XTT assay
    Antiproliferative activity against human NCI-H460 cells by XTT assay
    [PMID: 19220018]
    NCI-H460 IC50
    0.15 μM
    Compound: Nocodazole
    Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    [PMID: 12852768]
    NCI-H460 IC50
    0.25 μM
    Compound: Nocodazole
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    NCI-H460 IC50
    2.29 μM
    Compound: Nocodazole
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 34095841]
    P388 IC50
    > 5 μM
    Compound: nocodazole
    Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
    Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
    [PMID: 19220018]
    P388 IC50
    0.04 μM
    Compound: nocodazole
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    [PMID: 19220018]
    P388 IC50
    0.05 μM
    Compound: Nocodazole
    Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    P388 IC50
    0.05 μM
    Compound: nocodazole
    Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    P388 IC50
    0.07 μM
    Compound: nocodazole
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    P388 IC50
    0.07 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
    [PMID: 21705223]
    P388 IC50
    0.08 μM
    Compound: Nocodazole
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    P388 IC50
    0.08 μM
    Compound: nocodazole
    Antiproliferative activity against P388 cells by XTT assay after 48 hrs
    Antiproliferative activity against P388 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    P388 IC50
    0.17 μM
    Compound: Nocodazole
    Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
    Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    P388 IC50
    0.17 μM
    Compound: nocodazole
    Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
    Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
    [PMID: 17181164]
    PANC-1 GI50
    < 0.01 μM
    Compound: Nocodazole
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    [PMID: 27688193]
    PANC-1 GI50
    < 0.01 μM
    Compound: Nocadazole
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    [PMID: 25827522]
    PANC-1 GI50
    0.029 μM
    Compound: Nocodazole
    Anticancer activity against human PANC1 cells after 48 hrs by SRB assay
    Anticancer activity against human PANC1 cells after 48 hrs by SRB assay
    [PMID: 27130357]
    PC-3 IC50
    1.84 μM
    Compound: Nocodazole
    Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    PC-3 IC50
    2.5 μM
    Compound: Nocodazole
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    RKO IC50
    > 10 μM
    Compound: Nocodazole
    Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
    Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
    [PMID: 20537765]
    RKO IC50
    > 10 μM
    Compound: nocodazole
    Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
    Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
    [PMID: 17181164]
    RKO IC50
    > 10 μM
    Compound: nocodazole
    Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
    Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
    [PMID: 19220018]
    RKO IC50
    > 14 μM
    Compound: nocodazole
    Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
    Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
    [PMID: 17973361]
    RKO IC50
    0.11 μM
    Compound: Nocodazole
    Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
    Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
    [PMID: 20537765]
    RKO IC50
    0.11 μM
    Compound: nocodazole
    Cytotoxicity against human RKO cells after 48 hrs by XTT assay
    Cytotoxicity against human RKO cells after 48 hrs by XTT assay
    [PMID: 17973361]
    RKO IC50
    0.11 μM
    Compound: nocodazole
    Antiproliferative activity against RKO cells by XTT assay after 48 hrs
    Antiproliferative activity against RKO cells by XTT assay after 48 hrs
    [PMID: 17181164]
    RKO IC50
    0.11 μM
    Compound: nocodazole
    Antiproliferative activity against human RKO cells by XTT assay
    Antiproliferative activity against human RKO cells by XTT assay
    [PMID: 19220018]
    SF-268 IC50
    0.3 μM
    Compound: Nocodazole
    Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
    Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    SF-268 IC50
    0.3 μM
    Compound: Nocodazole
    Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
    Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    SF-268 IC50
    0.3 μM
    Compound: nocodazole
    Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
    Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    SF-268 IC50
    0.3 μM
    Compound: nocodazole
    Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
    Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    SF-268 IC50
    0.3 μM
    Compound: nocodazole
    Antiproliferative activity against human SF268 cells by XTT assay
    Antiproliferative activity against human SF268 cells by XTT assay
    [PMID: 19220018]
    SF-268 IC50
    0.3 μM
    Compound: Nocodazole
    Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    [PMID: 12852768]
    SGC-7901 IC50
    0.08 μM
    Compound: 1
    Growth inhibition of human SGC7901 cells after 72 hrs by MTT assay
    Growth inhibition of human SGC7901 cells after 72 hrs by MTT assay
    [PMID: 25262051]
    SGC-7901 IC50
    0.085 μM
    Compound: 4
    Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    10.1039/C5MD00150A
    SK-BR-3 IC50
    0.084 μM
    Compound: Nocodazole
    Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
    Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
    [PMID: 22850214]
    SK-N-SH IC50
    < 0.1 μM
    Compound: Nocodazole
    Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay
    10.1039/C0MD00263A
    SK-N-SH GI50
    0.65 μM
    Compound: Nocodozole
    Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay
    [PMID: 20529689]
    SK-N-SH GI50
    0.66 μM
    Compound: Nocodozole
    Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
    Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
    [PMID: 21106458]
    SK-OV-3 IC50
    0.08 μM
    Compound: Nocodazole
    Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    SK-OV-3 IC50
    0.17 μM
    Compound: Nocodazole
    Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
    [PMID: 21705223]
    SK-OV-3 IC50
    0.17 μM
    Compound: Nocodazole
    Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
    Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
    [PMID: 20537765]
    SK-OV-3 IC50
    0.17 μM
    Compound: nocodazole
    Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
    [PMID: 17973361]
    SK-OV-3 IC50
    0.17 μM
    Compound: nocodazole
    Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
    Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
    [PMID: 17181164]
    SK-OV-3 IC50
    0.17 μM
    Compound: nocodazole
    Antiproliferative activity against human SKOV3 cells by XTT assay
    Antiproliferative activity against human SKOV3 cells by XTT assay
    [PMID: 19220018]
    SK-OV-3 IC50
    0.17 μM
    Compound: Nocodazole
    Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
    [PMID: 12852768]
    SW480 IC50
    0.12 μM
    Compound: Nocodazole
    Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
    Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
    [PMID: 21563750]
    U2OS EC50
    50 nM
    Compound: Nocodazole
    Induction of mitotic arrest in human U2OS cells assessed as mitotic index after 72 hrs by microscopic analysis
    Induction of mitotic arrest in human U2OS cells assessed as mitotic index after 72 hrs by microscopic analysis
    [PMID: 24900887]
    Z-138 IC50
    0.31 μM
    Compound: Nocodazole
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    [PMID: 37252100]
    In Vitro

    Nocodazole exhibits good affinity toward c-KIT, with a Kd value of 1.6 μM in highly malignant human cancer cells. Nocodazole displays good binding affinity toward the components of the mitogen-activated protein kinase (MAPK) pathway, such as BRAF (Kd=1.8 μM), BRAF(V600E) (Kd=1.1 μM), MEK1 (Kd=1.7 μM), and MEK2 (Kd=1.6 μM)[1]. Nocodazole has the highest affinity for αβIV and the lowest affinity for αβIII[2].
    Nocodazole (1 nM) induces apoptosis of COLO 205 cancer cells[3].
    Nocodazole (≥ 30 µg/mL) significantly increases the percentage of annexin-V-binding cells without significantly modifying average forward scatter of human erythrocytes[4].
    In CHO cells, the addition of 1 nM Nocodazole, a concentration that suppresses microtubule dynamics, slows migration and increases the frequency and duration of resting states, but the directionality of the cells is maintained. In contrast to the effects of the low drug concentration, the addition of 70 nM Nocodazole, a concentration that eliminates the microtubule network, causes cells to move much more randomly, i.e., the directionality of the cells toward the wound is lost[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Nocodazole (5 mg/kg/three times per week, i.p.) has antitumor effects in athymic mice bearing COLO 205 tumor xenografts. Nocodazole (1 nM) + R-41400 dramatically increase the levels of p21/CIP1 and p27/KIP1 protein in the tumor tissues[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    301.32

    Formula

    C14H11N3O3S

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to brown

    SMILES

    O=C(OC)NC1=NC2=CC=C(C(C3=CC=CS3)=O)C=C2N1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 16.67 mg/mL (55.32 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3187 mL 16.5937 mL 33.1873 mL
    5 mM 0.6637 mL 3.3187 mL 6.6375 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2 mg/mL (6.64 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 5 mg/mL (16.59 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.59%

    References
    Cell Assay
    [3]

    Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    COLO 205 cells are grown in RPMI 1640 supplemented with 10% FCS. Cells are harvested through two consecutive trypsinizations, centrifuged at 300×g; for 5 min, washed twice, and resuspended in sterile phosphate-buffered saline (PBS). Cells (5×105) in 0.1 mL are injected subcutaneously between the scapulae of each nude mouse. After transplantation, tumor size is measured with calipers, and the tumor volume is estimated. Once tumors reach a mean size of 200 mm3, animals receive intraperitoneal injections of DMSO (25 μL), R-41400 (50 mg/kg), nocodazole (5 mg/kg), or R-41400 + nocodazole three times per week for 6 wk.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3187 mL 16.5937 mL 33.1873 mL 82.9683 mL
    5 mM 0.6637 mL 3.3187 mL 6.6375 mL 16.5937 mL
    10 mM 0.3319 mL 1.6594 mL 3.3187 mL 8.2968 mL
    15 mM 0.2212 mL 1.1062 mL 2.2125 mL 5.5312 mL
    20 mM 0.1659 mL 0.8297 mL 1.6594 mL 4.1484 mL
    25 mM 0.1327 mL 0.6637 mL 1.3275 mL 3.3187 mL
    30 mM 0.1106 mL 0.5531 mL 1.1062 mL 2.7656 mL
    40 mM 0.0830 mL 0.4148 mL 0.8297 mL 2.0742 mL
    50 mM 0.0664 mL 0.3319 mL 0.6637 mL 1.6594 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Nocodazole
    Cat. No.:
    HY-13520
    Quantity:
    MCE Japan Authorized Agent: